吉因加科技冲刺港股IPO

Core Viewpoint - The company, GeneTech (Shaoxing) Co., Ltd., is seeking to list on the Hong Kong Stock Exchange, despite experiencing significant financial losses in recent years, particularly in 2024 and 2025 [1][2]. Group 1: Company Overview - GeneTech is a leading precision medicine company in China, integrating AI capabilities into the biomarker value chain [1]. - The company has developed a multi-omics platform that combines foundational models with intelligent AI, enabling a full-chain capability from biomarker discovery to commercialization [1]. - GeneTech offers three main solutions: precision diagnostics, drug development empowerment, and clinical research and translation [1]. Group 2: Business Performance - GeneTech's revenue has fluctuated significantly in recent years, with reported revenues of 1.815 billion yuan in 2022, 473 million yuan in 2023, 557 million yuan in 2024, and 285 million yuan in the first half of 2025 [2]. - The company's net profit has shown a downward trend, with figures of 372 million yuan in 2022, 54.127 million yuan in 2023, and losses of 424 million yuan and 414 million yuan in the first halves of 2024 and 2025, respectively [2]. - As of June 2025, GeneTech has served over 1,000 hospitals, including 30 of China's top 100 hospitals, and has established partnerships with over 200 pharmaceutical companies and 500 clinical research institutions [1].